Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Pain × cabozantinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 9 Neoplasms 3 Kidney Neoplasms 3 Carcinoma 3 Prostatic Neoplasms 2 Carcinoma, Medullary 2 Carcinoma, Hepatocellular 2 von Hippel-Lindau Disease 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Thyroid cancer, follicular 1 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Refractory Differentiated Thyroid Gland Carcinoma 1 Pain 1 Non functioning pancreatic endocrine tumor 1 Neuroendocrine Tumors 1 Lymphatic Metastasis 1 Liver Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Adenoma, Islet Cell 1 Adenocarcinoma, Follicular 1

Interventions

Fentanyl 7 Zoledronic Acid 6 Radiotherapy 6 Ibandronic Acid 6 Morphine 5 Ketamine 5 Hydromorphone 5 nabiximols 4 Tapentadol 4 Oxycodone 4 Analgesia 4 alvimopan 3 Lidocaine 3 Acupuncture Therapy 3 Acetaminophen 3 Tetrodotoxin 2 Ropivacaine 2 Gabapentin 2 Docetaxel 2 resiniferatoxin 1 oxycodone-acetaminophen 1 oxycodone naloxone combination 1 ixabepilone 1 cabozantinib 1 Triamcinolone Acetonide 1 Triamcinolone 1 Therapeutics 1 Taxes 1 Sugars 1 Standard of Care 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01522443 2018-05-23

COMET-2

Exelixis

Phase 3 Terminated

119 enrolled 21 charts

Pain, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡